Abstract: The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-?4?7 antibody, e.g., vedolizumab, to a human subject in need thereof.

Abstract: The present invention features, inter alia, methods of treating (a) a patient who has been diagnosed with a hematopoietic cancer or (b) a population of patients who have been diagnosed with a hematopoietic cancer with a fixed dose of tamibarotene or a pharmaceutically acceptable salt thereof. The tamibarotene is administered daily, for a prescribed number of days, at 8-14 (e.g., 12 mg/day) regardless of the patient's weight or body surface area, and may be administered as the sole therapeutic agent or in combination with one or more of the additional therapeutic agents described herein.

Abstract: Systems and methods of evolving music tracks are disclosed. One example method providing a plurality of Artificial Neural Networks (ANNs). Each of the ANNs uses a time signature input. The method also includes producing a rhythm from each of the plurality of ANNs. The method also includes evolving a next generation of ANNs based upon a user selection of one of the plurality of rhythms and upon the previous generation of ANNs. An example system includes a plurality of Compositional Pattern Producing Networks (CPPNs). Each of the CPPNs uses a time signature input to produce a rhythm. The system also includes logic configured to receive a selection of one or more of the CPPN, and logic configured to generate at least one evolved CPPN based upon the selection.

Abstract: Systems and methods of generating music tracks are disclosed. One such method, for generating one type of music track from another type of music track, is implemented in a computer. The method includes the steps of receiving a music track input having a first type into an artificial neural network (ANN), and producing a music track output having a second type from the ANN, based upon the music track input having the first type.

Abstract: Systems and methods of evolving music tracks are disclosed. One example method providing a plurality of Artificial Neural Networks (ANNs). Each of the ANNs uses a time signature input. The method also includes producing a rhythm from each of the plurality of ANNs. The method also includes evolving a next generation of ANNs based upon a user selection of one of the plurality of rhythms and upon the previous generation of ANNs. An example system includes a plurality of Compositional Pattern Producing Networks (CPPNs). Each of the CPPNs uses a time signature input to produce a rhythm. The system also includes logic configured to receive a selection of one or more of the CPPN, and logic configured to generate at least one evolved CPPN based upon the selection.

Abstract: The present invention encompasses pre-mixed formulations comprising a GLP-1 polypeptide and a basal insulin.

Abstract: The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase.

Abstract: The present invention encompasses compositions wherein a GLP-1 compound is complexed with a basic polypeptide. The compositions provide a prolonged duration of action and can be administered by the pulmonary route.

Abstract: The present invention provides means to improve the chemical stability of aqueous, parenteral pharmaceutical compositions comprising a polypeptide and glycerin. Reactive aldehydes are identified in commercial glycerins, and means for reducing such are provided. Convenient means are provided to assay for reactive aldehydes in glycerin, and a strong linear correlation between the level of reactive aldehydes in glycerin and chemical stability of compositions comprising a polypeptide and glycerin is demonstrated. The invention includes aqueous compositions comprising a polypeptide and glycerin having improved chemical stability compared to compositions previously known.

Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

Abstract: The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase.

Abstract: The present invention encompasses pre-mixed formulations comprising a GLP-1 polypeptide and a basal insulin.

Abstract: The present invention provides means to improve the chemical stability of aqueous, parenteral pharmaceutical compositions comprising a polypeptide and glycerin. Reactive aldehydes are identified in commercial glycerins, and means for reducing such are provided. Convenient means are provided to assay for reactive aldehydes in glycerin, and a strong linear correlation between the level of reactive aldehydes in glycerin and chemical stability of compositions comprising a polypeptide and glycerin is demonstrated. The invention includes aqueous compositions comprising a polypeptide and glycerin having improved chemical stability compared to compositions previously known.

Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

Abstract: A method is disclosed for evaluating and/or selecting sonar systems and sonar sensors is provided that results in a performance rating that represents both the magnitude and consistency of detection of targets positioned at different depths. In a preferred embodiment wherein a sonar system includes at least one source and at least one receiver, the performance rating related to target detection, is plotted for each of a plurality of source and receiver depths. A dynamic range sensitivity factor is selected that provides sensitivity in the performance rating with respect to consistency of the detection range at different depths. The dynamic range sensitivity factor is preferably selected between zero and an inverse of a scaling factor related to a maximum detection range and a minimum detection range for a particular source and receiver depth relationship.

Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.